Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo‐controlled study in healthy adults
Coadministration of zavegepant with sumatriptan was safe and without PD or PK interactions in healthy adults.
Authors
- Jing Liu (ORCID: https://orcid.org/0000-0001-9481-5961)
- Richard Bertz (ORCID: https://orcid.org/0009-0006-4593-1310)
- Mary Donohue (ORCID: https://orcid.org/0009-0006-0450-5702)
- Robert Croop (ORCID: https://orcid.org/0009-0004-0151-1192)
- Beth Morris (ORCID: https://orcid.org/0000-0001-5346-4173)
- Kyle Matschke (ORCID: https://orcid.org/0009-0003-2043-851X)
- Jennifer Madonia (ORCID: https://orcid.org/0009-0000-8060-8478)
- Matt S. Anderson (ORCID: https://orcid.org/0009-0005-3940-7056)
- Rajinder Bhardwaj (ORCID: https://orcid.org/0009-0005-2720-2192)
Institutions
- Pfizer (United States) (US)
- Biohaven Pharmaceuticals (United States) (US)
- Certara (United States) (US)
- Integra LifeSciences (United States) (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-10-04
- DOI
- https://doi.org/10.1111/head.14853
- Citations
- 8
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.08
Funders
- Pfizer